Edgewise Therapeutics, Inc. EWTX
We take great care to ensure that the data presented and summarized in this overview for Edgewise Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EWTX
View all-
Orbimed Advisors LLC San Diego, CA15MShares$407 Million10.86% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$241 Million3.85% of portfolio
-
Baker Bros. Advisors LP New York, NY6.16MShares$167 Million1.82% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$163 Million0.0% of portfolio
-
Novo Holdings Hellerup, G75MShares$136 Million10.85% of portfolio
-
Janus Henderson Group PLC London, X04.98MShares$135 Million0.07% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$122 Million4.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$121 Million0.0% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.41MShares$92.3 Million7.18% of portfolio
-
Perceptive Advisors LLC New York, NY2.69MShares$72.8 Million2.39% of portfolio
Latest Institutional Activity in EWTX
Top Purchases
Top Sells
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Insider Transactions at EWTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 06
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
900
-5.85%
|
$27,900
$31.13 P/Share
|
|
Feb 06
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+5.53%
|
$11,700
$13.11 P/Share
|
|
Feb 06
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,200
-7.47%
|
$36,000
$30.13 P/Share
|
|
Feb 06
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+6.95%
|
$0
$0.18 P/Share
|
|
Feb 05
2025
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
10,000
-37.26%
|
$300,000
$30.03 P/Share
|
|
Feb 05
2025
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+27.15%
|
$10,000
$1.93 P/Share
|
|
Feb 05
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
8,636
-37.36%
|
$259,080
$30.03 P/Share
|
|
Feb 05
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+27.2%
|
$0
$0.18 P/Share
|
|
Feb 05
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,015
-35.03%
|
$240,450
$30.02 P/Share
|
|
Feb 05
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,015
+25.94%
|
$0
$0.18 P/Share
|
|
Jan 28
2025
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
25,000
-60.45%
|
$675,000
$27.63 P/Share
|
|
Jan 28
2025
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+37.67%
|
$175,000
$7.08 P/Share
|
|
Dec 30
2024
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
100,000
-87.06%
|
$2,700,000
$27.37 P/Share
|
|
Dec 30
2024
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+46.54%
|
$0
$0.18 P/Share
|
|
Dec 24
2024
|
Marc Semigran Chief Development Officer |
SELL
Open market or private sale
|
Direct |
29,709
-48.64%
|
$861,561
$29.87 P/Share
|
|
Dec 24
2024
|
Marc Semigran Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,709
+44.92%
|
$237,672
$8.94 P/Share
|
|
Oct 11
2024
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,000
+47.65%
|
$0
$0.71 P/Share
|
|
Sep 23
2024
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
20,922
-86.55%
|
$564,894
$27.63 P/Share
|
|
Sep 23
2024
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,922
+46.39%
|
$0
$0.71 P/Share
|
|
Sep 20
2024
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
7,162
-33.0%
|
$200,536
$28.29 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 579K shares |
|---|
| Open market or private sale | 518K shares |
|---|